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Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old
Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred
within a week of starting everolimus and an upward trend in the transaminase levels continued with supporting histopathologic
changes confirmed by liver biopsy. Within one week of drug discontinuation, his liver enzymes normalized to baseline.This report
includes a brief review of the pharmacokinetic properties of everolimus, a review of the relevant literature, and an analysis using
the RUCAM and Naranjo algorithms.
1. Introduction
Everolimus is a mammalian target of rapamycin (mTOR)
inhibitor that is FDA approved for use as an immunosup-
pressive agent in kidney and liver transplantation [1]. In liver
transplantation, everolimus is used with low dose tacrolimus
and steroids as a kidney-sparing agent to prevent cellular
rejection [2]. Everolimus is also approved for advanced cases
of breast cancer, pancreatic tumors, and advanced renal cell
carcinoma [1]. As a narrow therapeutic index drug, achieving
optimal exposure levels (trough concentration ranging from
3 to 8 ng/mL) is critical to its successful use [3].
The mTOR pathway is involved in several physiological
pathways including protein, nucleotide, and lipid synthesis.
mTOR is a protein kinase that regulates cell growth and cycle
progression of B and T lymphocytes from the IL-2 receptor to
the nucleus [4]. Consequently, it comes with a diverse range
of dose-dependent side effects including hyperlipidemia,
edema, wound healing complications, stomatitis, anemia,
proteinuria, and interstitial pneumonitis.
In this case, we discuss a patient on everolimus after
liver transplant and the histopathologic and laboratory value
changes indicative of drug-induced liver injury (DILI).
2. Case Presentation
A 56-year-old Caucasian male with nonalcoholic steato-
hepatitis (NASH) experienced progression to cirrhosis and
its complications including portal hypertension, esophageal
varices, and ascites. He had no other significant past medical
history. At the time of transplant in July 2015, the patient
weighed 228 lbs (BMI 34). He received a liver transplant and
was placed on amaintenance immunosuppressive regimen of
tacrolimus 9mg PO BID with a trough goal of 8-10 ng/mL,
mycophenolic acid (Myfortic) 720mg PO BID, and a pred-
nisone taper. The patient remained stable on this regimen
and had the following normal laboratory results at the begin-
ning of September (Figure 1): ALT 32 IU/L (normal=0-40),
AST 23 IU/L (normal= 5-40), alkaline phosphatase (ALP)
83 IU/L (normal= 40-100), gamma-glutamyl transpeptidase
(GGT) 36 IU/L (normal=10-64), total bilirubin 0.3mg/dL
(normal=0.3-1.9mg/dL), BUN 26 (normal 6-20mg/dL), and
Scr 1.18 (normal 0.67-1.17mg/dL) and INR 1.1.
On September 3, 2015, the patient was switched from
mycophenolic acid to everolimus as part of a clinical research
study investigating the renal sparing effects of everolimus
to target a lower tacrolimus trough concentration of 3-
5 ng/mL. At the time of everolimus introduction, the patient’s
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Figure 1: Patient’s liver enzyme levels and level of immunosuppression after receiving a liver transplant in July 2015.The blue arrow represents
the date of the transplant and the shaded area between the red arrows represents the everolimus exposure period (start: 9/3/15; end: 12/1/15).
weight was down to 210 lbs (BMI 31.9) and laboratory values
that would impact the pharmacokinetics of everolimus were
within a normal range: Hgb 12mg/dL and albumin 3.7 g/dL.
After the patient’s first everolimus dose on a starting regimen
of 1mg PO BID, he reported new onset pain to the right flank
area. At this time, there was an upward trend in his liver
enzymes, ALT (69 IU/L), AST (35 IU/L), ALP (99 IU/L), and
GGT (58 IU/L). The everolimus trough was subtherapeutic
until late October when a trough of 3.8 ng/mL was achieved
on a dose of 3mg PO qam and 2.5mg PO qpm (Figure 1).
In early October, the patient experienced increasing
liver enzymes (ALT=84 IU/L; AST= 42 IU/L; ALP=102 IU/L;
GGT=53 IU/L; total bilirubin 0.23mg/dL) with a tacrolimus
trough concentration of 8.2, so a liver biopsy was performed
to rule out rejection. The results showed mild portal inflam-
mation with lymphocytes, pericentral sinusoidal dilatation
with no hepatic plate atrophy, and inflammation adjacent
to the central vein (RAI score = 1 out of 9). The trichrome
stain did not have any perisinusoidal staining to indicate
chronicity, nor was there duct injury, duct loss, cholesta-
sis, endothelitis, or steatosis. Immunostains for hepatitis
B surface antigen (HBsAg) and hepatitis B core antigen
(HBcAg) were also negative. There was no report of fever,
chills, dark-colored urine, or jaundice or any evidence of an
acute hypersensitivity reaction (fever/rash).The immune cell
function (ImmuKnow) assay was 338 ng/mL in late October
close to the time of the biopsy (10/26/15). It was confirmed
that there was no evidence of acute rejection.
By the end of November, two and a half months from
the start of everolimus, the patient’s serum liver enzymes
reached their highest values, ALT (149 IU/L), AST (81 IU/L),
and ALP, (215 IU/L) and the ImmuKnow assay done at this
time resulted in a level of 412 ng/mL. Tacrolimus doses
had not been changed and troughs ranged from 6.9 to
9.8 ng/mL. A second liver biopsy was done on 11/30/15 that
showed mild patchy sinusoidal dilatation and focal mild
inflammatory infiltrate with lymphocytes, eosinophils, and
rare acidophil bodies (Figure 2). There was no evidence of
acute cellular rejection (RAI score= 1 out of 9), but the
presence of eosinophils and focal mild portal inflammation
was consistent with the possibility of drug injury. Everolimus
was discontinued on December 1, 2015, and the patient went
back to a regimen of tacrolimus 5mg BID and mycophenolic
Figure 2: Patient’s second biopsy done on 11/30/2015 showing
features of DILI including portal eosinophils and rare acidophil
bodies.
acid 720mg BID. After one week, the liver enzymes returned
to normal: ALT (22 IU/L), AST (20 IU/L), ALP (105 IU/L),
and total bilirubin (0.6mg/dL). Since discontinuation, the
patient denied pain and dizziness and reported improved
energy.
3. Discussion
To our knowledge, this is the first report of everolimus
associated DILI. A DILI score model was created to better
predict the potential of a drug to cause liver injury and
the severity of the injury based on the lipophilicity of the
drug (log P ≥3), covalent binding of reactive metabolites,
and the daily dose of the oral medication (≥ 100mg) [5].
Everolimus has not been studied in this model directly.
However, it does have the property of high lipophilicity with
a log P of 5.01, a property associated with greater rates of
mitochondrial toxicity and DILI [5, 6]. Secondly, as opposed
to sirolimus, it has a stable 2-hydroxy-ethyl substitution at
position 40, improving its oral bioavailability [7, 8]. In our
patient, the daily dose of everolimus never exceeded 5.5mg
daily, far lower than the 100mg threshold for the model.
The importance of this property for a drug like everolimus
may not be significant because there is a poor correlation
between the dose and actual systemic exposure of the drug;
a stronger correlation is seen between the AUC and trough
concentration [7].
Case Reports in Transplantation 3
Despite the similarity in chemical structures between
sirolimus and everolimus, only sirolimus has been included
in the FDA’s Liver Toxicity Knowledge Base (LTKB) Database
as being of “less DILI concern.” This is based on both drug-
labeling studies of sirolimus and verified causality evidence of
hepatotoxicity with elevated trough levels [9–11]. A reference
drug list for risk of DILI in humans ranks everolimus as
having “ambiguous DILI concern” when taking into account
the drug-labeling studies as well as verified causality evidence
[9]. Based on the clinical trial studies, everolimuswas initially
ranked as having “less DILI concern” due to ≤ 10% of patients
in each test group having elevations in alkaline phosphatase
and liver transaminases [10]. However, the verified DILI
concern is still “ambiguous” because there have been no
verified causality evidence reports on DILI [9].
In order to rule out other causalities for DILI in this
patient, we examined the DILI potential of his concomitant
medications. These included tacrolimus, prednisone, sul-
famethoxazole/trimethoprim (TMP-SMZ), metformin, glip-
izide, and propranolol. Tacrolimus, prednisone, and TMP-
SMZ are not listed as drugs with a significant risk of
DILI in humans based on the reference compiled by Chen
et al. [9]. In postmarketing reports, tacrolimus has only
been associated with mild to moderate elevations in serum
aminotransferases in 5-10% of patients and any elevations are
mild, asymptomatic, and self-limiting [12]. Long term and
high doses of prednisone and methylprednisolone (500mg)
[13] have been associated with NASH exacerbations, with
liver enzyme elevations, and with liver histology showing
hepatitis with steatosis, chronic inflammation, and Mallory
bodies, which were not consistent with liver biopsy in this
patient [11]. Our patient was only on a small oralmaintenance
dose of 2.5mg daily. TMP-SMZ can cause mild elevations
in ALT that do not proceed to more severe liver injury or
jaundice, but in postmarketing reports, the onset is usually
within a few days or weeks of starting the medication and
resolves within 2-4 weeks [11]. Though idiosyncratic liver
injury has been reported with TMP-SMZ with features of
drug allergies (eosinophilia), the time course of onset was not
consistent with the literature [11]. In our case, TMP-SMZ was
started in July 2015 and the patient’s liver enzymes (as evident
in the graph) were still stable and within normal limits at this
time prior to the start of everolimus in September 2015.
Propranolol has been listed as a drug of “ambiguous
DILI concern” by Chen et al. and has been rated as an
unlikely cause of clinically apparent liver injury. Its rating is
based on case reports showing a pattern of serum enzyme
elevations that are hepatocellular in nature with typical onset
of 2 to 24 weeks [9, 11]. These elevations have been seen
in 2% of patients using propranolol and are transient and
asymptomatic and tend to resolve even as the patient con-
tinues the medication [11]. There are no causal associations
because these case reports included patients who were on
other well-known hepatotoxic drugs [11]. This patient had
started propranolol on 8/28/15, so while the timecourse of
propranolol use may be in conjunction with the time for
enzyme elevationwith its use, the pattern of enzyme elevation
was not hepatocellular.
Thoughmetformin was initially listed as a drug with “no-
DILI concern,” there have been close to twenty case reports
in the literature of hepatotoxicity with metformin after 4 to 8
weeks of use [14].Minor elevations in liver enzymes have been
reported to occur during metformin therapy in less than 1%
of patients and typically the timing of the injury occurs soon
after the agent is started, not during long term therapy [11].
Our patient had been taking metformin for three months, so
the likelihood ofmetformin causing his DILI is low. Glipizide
has not been identified as an agent ofDILI concern andminor
elevations in liver enzymes occur in <1% of patients which
is comparable to what can be expected with placebo [9, 11].
Though these medications were started after transplant, the
timecourse of transaminase elevations does not correspond
to the literature reports.
Additionally, we checked to ensure that elevations in liver
enzymes and liver injury were not due to drug interactions.
The only major interactions noted were between amlodipine
(a CYP3A4 inhibitor) and tacrolimus, leading to increased
levels, and prednisone (a CYP3A4 inducer) and tacrolimus
leading to decreased levels and potential for transplant
rejection [15]. Tacrolimus trough levels were monitored
throughout this patient’s treatment and were within the
trough goal throughout the time of liver injury. Therefore, it
is unlikely that drug-drug interactions played a role.
The classification of DILI based on phenotype appears
to be mixed [11]. At the peak of the patient’s enzyme
elevations, the ratio of [ALT/ULN]/[Alk P/ULN] was 2.23.
This was based on the patient’s enzymesmeasured on 11/23/15
in which the ALT was 149 U/L (ULN= 40) and the Alk
Phos was 215 IU/L (ULN= 129) [11, 16]. Ratios of >5 define
hepatocellular, <2 cholestatic, and between 2 and 5 mixed
pattern of enzymes [11, 16]. In hepatocellular injury, the ALT
is usually >three times the upper limit of normal (ULN),
alkaline phosphatase is more than two times the ULN, or
total bilirubin is more than twice the ULN [11, 16]. Though
elevations to this extent were not evident within the first
month, the values did increase and eventually reached levels
of ALT or AST that were >3X the ULN and an ALP > 2X the
ULN by the end of two months.This indicates that the injury
may be mixed hepatocellular and cholestatic.
We suspected everolimus induced DILI based on the
chronological association with liver enzyme abnormalities,
the pathology findings, and the properties of the drug. We
also applied the more standardized causality assessment
for drug-induced hepatotoxicity, RUCAM (Roussel Uclaf
Causality Assessment Method). This method evaluates drug-
induced liver injury based on seven criteria: (1) time to onset
of the injury following start of the drug; (2) subsequent course
of injury after stopping the drug (time to enzyme normal-
ization after cessation of drug); (3) specific risk factors (age,
alcohol use, and pregnancy); (4) use of other medications
with a potential for liver injury; (5) exclusion of other causes
of liver disease; (6) known potential for hepatotoxicity of the
implicated drug; and (7) response to rechallenge [16]. This
data is scored and categorized as highly probable, probable,
possible, or excluded. RUCAM is specific to liver injury
and has been evaluated for accuracy, reproducibility, and
intraobserver variability with the advantage of being more
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Table 1: Adverse drug reaction probability scale (Naranjo) [17].
Question Yes No Do Not Know Score
1. Are there previous conclusive reports on this reaction? +1 0 0 0
2. Did the adverse event appear after the suspected drug was administered? +2 -1 0 +2
3. Did the adverse event improve when the drug was discontinued or a specific
antagonist was administered? +1 0 0 +1
4. Did the adverse event reappear when the drug was readministered? +2 -1 0 0
5. Are there alternative causes that could on their own have caused the reaction?
(alternatives have been excluded =no) -1 +2 0 +2
6. Did the reaction reappear when a placebo was given? -1 +1 0 0
7. Was the drug detected in blood or other fluids in concentrations known to be
toxic? +1 0 0 0
8. Was the reaction more severe when the dose was increased or less severe when
the dose was decreased? (reaction was less severe when the dose was decreased) +1 0 0 +1
9. Did the patient have a similar reaction to the same or similar drugs in any
previous exposure? +1 0 0 0
10. Was the adverse event confirmed by any objective evidence? +1 0 0 +1
Total Score: 7
objective [11]. The range of possible RUCAM scores is −9 to
+14 with 0 or less indicating that the drug is “excluded” as a
cause, 1 to 2 indicating that it is “unlikely,” 3 to 5 indicating
that it is “possible,” 6 to 8 indicating that it is “probable,”
and greater than 8 indicating that it is “highly probable.” In
our patient the RUCAM score was 8, which indicates that the
link of liver injury as an adverse drug reaction of everolimus
is probable (Figure 3). While RUCAM is advantageous due
to its specificity to liver injury in assessing causality, one
drawback is in criterion #6 which asks the observer to
consider the known publications of the reaction [16]. The
model does not account for differences in type or quantity
of publications.
We also applied a second assessment of causality using
the Naranjo scale. While the Naranjo scale is not specific
for liver injury, it is a widely accepted scale for assessing
drug-associated reactions [17]. The assessment takes into
consideration ten factors: (1) any previous reports of a
reaction; (2) the appearance of the adverse event after starting
the drug; (3) improvement in the reaction after drug discon-
tinuation; (4) reappearance of the reaction when the drug is
readministered; (5) other possible causes; (6) reappearance
of the reaction when placebo is given; (7) detection in the
blood or fluids of toxic drug concentrations; (8) worsening
or improvement of the reaction with an increase or decrease
in dose; (9) previous similar reaction to the drug; and (10)
confirmation by objective evidence [17]. The scoring system
ranges from −4 to +13 with a score of 0 or less being
“doubtful,” 1 to 4 being “possible,” 5 to 8 being “probable,”
and 9 or higher being “definite” adverse drug reaction. Based
on the Naranjo scale, the likelihood of everolimus causing
the liver injury in our patient was 7 (or probable) (Table 1).
A probable causality on this scale means that the reaction
(liver injury) followed a reasonable temporal sequence after
initiation of the drug andwas confirmed by withdrawal of the
drug.
Figure 3: Roussel Uclaf Causality Assessment Method (RUCAM)
[16] shows a causality assessment of liver injury based on 7 criteria.
The score of 8 indicates that it is probable that the liver injury was
due to everolimus.
4. Conclusion
This case documents an association between everolimus and
DILI. Use of everolimus in this post-liver transplant patient
led to elevations in AST, ALT, and ALP consistent withmixed
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hepatocellular and cholestatic liver injury over a period of
three months. In addition, the liver biopsy confirmed the
finding of DILI based upon the histological characteristics,
notably the presence of eosinophils, rare acidophil bodies,
and focal mild portal inflammation. Finally, all other con-
comitant medications have been sufficiently ruled out as
being the cause of DILI. The pharmacokinetic characteristics
of everolimus coupled with the temporal correlation, his-
tologic findings, and positive RUCAM and Naranjo scores
point to everolimus being the likely cause of this patient’s
DILI. Future investigations into the factors that may have
increased this patient’s susceptibility should be explored.
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